Abbisko Therapeutics Co., Ltd.

After a couple of months of talks, Merck KGaA has inked a deal to buy SpringWorks Therapeutics which will expand its presence in the US and sharpen the firm’s focus in rare diseases and cancer. The pu

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Daiichi Sankyo Tries Wayfinder’s

Merck KGaA only has two-late stage candidates in its pipeline but CEO Belén Garijo has told Scrip that the German company is laser-focused on adding more assets. Speaking at Merck’s annual press con

Following a couple of fairly disastrous trial failures, Merck KGaA can finally celebrate a hit. The colony stimulating factor-1 (CSF-1) inhibitor pimicotinib, originated by China-based Abbisko and lic